idarubicin has been researched along with Leukemia, Smoldering in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Bseiso, AW; Estey, E; Kantarjian, H | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Itoh, R; Mizuno, T; Morita, K; Suzuki, H; Tanaka, I | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Berrebi, A; Polliack, A | 1 |
| Johnson, E; Parapia, LA | 1 |
7 trial(s) available for idarubicin and Leukemia, Smoldering
| Article | Year |
|---|---|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
10 other study(ies) available for idarubicin and Leukemia, Smoldering
| Article | Year |
|---|---|
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Tretinoin; Vincristine | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Angiodysplasia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Emergencies; Enterocolitis; Gastrointestinal Hemorrhage; Humans; Idarubicin; Jejunal Diseases; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone; Vincristine | 1998 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.
Topics: Administration, Oral; Anemia, Refractory, with Excess of Blasts; Drug Evaluation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute | 1990 |
Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Daunorubicin; Humans; Idarubicin; Recurrence; Remission Induction; Time Factors | 1987 |